Clinical Trials Logo

Filter by:
NCT ID: NCT05241093 Recruiting - Clinical trials for Relapsed or Refractory Acute Myeloid Leukemia (AML)

A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Start date: March 29, 2022
Phase: Phase 2
Study type: Interventional

This is a single-arm, open, multicenter, phase 2 study to evaluate the efficacy, safety and pharmacokinetics of HYLM-122 in combination with cytarabine in Chinese subjects with FLT3 positive relapsed or refractory acute myeloid leukemia.

NCT ID: NCT05241028 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer

Start date: May 1, 2022
Phase: Phase 2
Study type: Interventional

This is a prospective, multi-center, single-arm, phase 2 study aiming to assess the efficacy and safety of adjuvant use of Ensartinib in stage IB-IIIA non-small cell lung cancer (NSCLC) with positive ALK-fusion. Enrolled patients will take Ensatinib for 3 years or until recurrence of the disease or intolerable toxicity, following complete tumour resection with or without adjuvant standard chemotherapy.

NCT ID: NCT05240950 Recruiting - Colorectal Cancer Clinical Trials

Anti-CEA CAR-T Cells to Treat Colorectal Liver Metastases

Start date: August 25, 2022
Phase: Phase 1
Study type: Interventional

Recurrence of liver metastasis in colorectal cancer after R0 resection is mainly due to the invisible minimal residual disease, which are the main factors leading to metastasis and recurrence. Positive circulating tumor DNA (ctDNA) is the direct evidence of the minimal residual disease (MRD). In recent years, Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) has made great breakthroughs, and has achieved good therapeutic effects in hematological tumors, but the research on solid tumors is limited. CEA expression is generally elevated in gastrointestinal tumors and is associated with high aggressiveness of tumors. At present, solid tumor cell therapy targeting CEA has been carried out at home and abroad, and has achieved certain efficacy. Anti-CEA CAR-T cells targeting CEA have been constructed in the pre-clinical study of this project, and the pre-clinical study results suggest good safety and effectiveness. Formation of minimal residual disease is associated with circulating blood in the residual tumor cells. Using this feature, this project intends to conduct a phase I clinical study on patients with minimal residual disease /positive ctDNA after R0 resection of colorectal cancer liver metastasis, so as to conduct preliminary exploration of anti-CEA CAR-T cell therapy, evaluate the safety and effectiveness of the therapy, determine the maximum tolerated dose (MTD), and provide guidance for subsequent drug dosage and clinical trials.

NCT ID: NCT05240911 Recruiting - Surgery Clinical Trials

Individual Dosing of Levothyroxine After Thyroidectomy

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

Recently, Zaborek et al. raised a Poisson regression model for levothyroxine(LT4) dosing scheme to predict individual dose of LT4 after thyroidectomy: daily LT4 dose=e[2.02+0.01(W)-0.0037(A )-0.098(F)-0.01(B)+0.007(T)+0.108(I)-0.014(M), where W is the weight of the patient (Kg), A is the age of the patient (years), and F is the gender (for women 1, male is 0), B represents the patient's body mass index (BMI), T represents the preoperative TSH level, I represents whether the patient takes iron preparations (1, if not 0), M represents whether the patient takes multivitamins/minerals (1, if not 0). We demonstrated its value with our retrospective data in our center. Therefore, we intend to carry out this randomized controlled trial in order to further evaluate the model. The clinical significance of this method can provide a basis for the future use in clinical optimization of individualized dosing.

NCT ID: NCT05240404 Recruiting - Clinical trials for Hepatocellular Carcinoma

Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma

Start date: July 1, 2020
Phase: Phase 2
Study type: Interventional

This phase II study is to evaluate the efficacy of the adjuvant immunotherapy after curative-intent ablation for recurrent hepatocarcinoma

NCT ID: NCT05239741 Recruiting - Clinical trials for Colorectal Neoplasms

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)

Start date: April 2, 2022
Phase: Phase 3
Study type: Interventional

In this study, Chinese participants with MSI-H or dMMR advanced colorectal cancer will be assigned to receive either pembrolizumab or the Investigator's choice of 1 of 6 standard of care (SOC) chemotherapy regimens for treatment. There is no hypothesis testing for this study.

NCT ID: NCT05239702 Recruiting - Ulcerative Colitis Clinical Trials

Clinical Study of Targeting CD7 CAR-T Cells in the Treatment of Autoimmune Diseases

Start date: February 28, 2022
Phase: Early Phase 1
Study type: Interventional

A Clinical Study on the Safety and Effectiveness of Targeting CD7 Chimeric Antigen Receptor T Cells in the Treatment of Autoimmune Diseases

NCT ID: NCT05239689 Recruiting - AML Clinical Trials

Clinical Study of CD38 CAR-T Cells in the Treatment of Hematological Malignancies

Start date: February 28, 2022
Phase: Early Phase 1
Study type: Interventional

Clinical Study on the Safety and Effectiveness of CD38 CAR-T Cells in the Treatment of CD38-positive Hematological Malignancies

NCT ID: NCT05239676 Recruiting - Lymphoma Clinical Trials

Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant Lymphoma

Start date: February 28, 2022
Phase: Early Phase 1
Study type: Interventional

Clinical Study on the Safety and Effectiveness of Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant Lymphoma

NCT ID: NCT05239663 Recruiting - Breast Cancer Clinical Trials

GM1 Prophylaxis for Post-chemotherapy Cognitive Impairment in Patients With Early Operable Breast Cancer

Start date: February 8, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the prophylactic effects of Ganglioside-Monosialic Acid in post-chemotherapy cognitive impairment in patients with early operable breast cancer.